Skip to main content
. Author manuscript; available in PMC: 2013 Jul 17.
Published in final edited form as: Dev Biol. 2007 May 3;307(2):237–247. doi: 10.1016/j.ydbio.2007.04.033

Figure 6. Fgf10+/−; Mlc1v-LacZ+/− lungs display reduced vascular development.

Figure 6

(A, B) E13.5 control (A) and Fgf10+/−; Mlc1v-LacZ+/− (B) lungs. Note the reduction in the presence of red blood cells in the mutant lung. (C, D) PECAM staining in control (C) and mutant (D) lung. Note the reduction in PECAM staining in the mutant. (E, F) Immunofluorescence with anti-Laminin antibodies on control (E) and mutant (F) E14.5 lungs. Note the abundant microvasculature in the mesenchyme of the control lung mesenchyme and the drastic reduction in development of the microvasculature in the mutant lung. DAPI: blue staining (G) Corrosion vascular cast of control and mutant E18.5 lungs. Note the reduced complexity of the vascular tree in the mutant lung. (g, g’) Corresponding high magnification of the peripheral part of the lung casts indicated in G by boxes. (H, I) Dissected left lobe of control (H) and mutant (I) P2 lungs. Note the large hemorrhagic areas in the mutant lung supporting the previously reported vascular defects.